Clinical and experimental studies on early diagnosis and improvement of therapeutic effect pancreatic cancer using monoclonal antibodies.

胰腺癌预后较差，治疗结果仍令人失望。为了改善胰腺癌的预后，我们建立了与胰腺癌有反应的单抗，并用这些抗体评价了胰腺癌早期诊断和靶向化疗的血清学标志。在药物传递系统的实际应用中，抗癌药物与葡聚糖偶联(ADM-OXD)被证明对人胰腺癌细胞株是有效的。对ADM-OXD的药学特性进行了研究，并开始了0期研究，建立了检测人MOAB与胃肠道肿瘤反应的新的免疫组织化学方法--改良的直接免疫过氧化物酶方法。在新的直接免疫组织化学方法中，从胃癌患者的脾细胞中提取的人单抗与胃、结肠癌和胰腺癌发生反应。评价了Km10、A10等鼠单抗与人免疫球蛋白的嵌合抗体的敏感性和特异性，并通过大规模培养探索了嵌合抗体用于临床应用的可能性。

Pancreatic carcinoma is associated with a poor prognosis, and the results of treatment are still disappointing. In an effort to improve the prognosis, the monoclonal antibodies (MoAb) reactive with pancreatic carcinoma were established and the serological markers for early diagnosis and the targeting chemotherapy for the disease were evaluated using these MoAb.In a practical application of drug delivery system, anticancer drug conjugated with dextran (ADM-OXD) was demonstrated to be effective for human pancreatic cancer cell lines. Studies on the pharmaceutical characteristics of the ADM-OXD were performed and the phase 0 study have been started.The new immunohistochemical assay, modified direct immunoperoxidase method for detection of human MoAb reactive with gastrointestinal carcinoma was established. A human MoAb derived from spleen cell of a gastric cancer patient was demonstrated to react with adenocarcinoma of stomach, colon and pancreas in the new direct immunohistochemical assay. The possible use of human MoAb for clinical application of targeting cancer chemotherapy was suggested to be possible in the future.The sensitivity and specificity of chimeric antibodies of mouse MoAb such as KM10 and A10 with human IgG were evaluated and the possible use of the chimeric antibodies for clinical application was found by means of large scale of culures.